Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  CardiovascularObesityGLP-1Issue 731GLP-1 Special Editions June 2014GLP-1 Special Editions Summer 2014

Reduced Systolic Blood Pressure Observed with Liraglutide

The reduced SBP was also weakly correlated with weight loss....

Advertisement

The study was done to quantify the effect of liraglutide on systolic blood pressure (SBP) and pulse in patients with type 2 diabetes (T2D), and assess the influence of covariates on observed SBP reductions, and was set up as a patient-level pooled analysis of six phase 3, randomized trial.

The results included 2792 randomized patients. In the intention-to-treat population (n=2783), mean [±SE] SBP reductions from baseline with liraglutide 1.2mg (2.7 [0.8] mmHg) and 1.8mg (2.9 [0.7] mmHg) once daily were significantly greater than with placebo (0.5 [0.9] mmHg; P=0.0029 and P=0.0004, respectively) after 26 weeks, and were evident after 2 weeks. Liraglutide was also associated with significantly greater SBP reductions than glimepiride and, at a dose of 1.8mg, insulin glargine and rosiglitazone. SBP reductions with liraglutide weakly correlated with weight loss (Pearson's correlation coefficient: 0.08-0.12; P≤0.0148). No dependence of these reductions on concomitant antihypertensive medications was detected (P=0.1304). Liraglutide 1.2 and 1.8mg were associated with mean increases in pulse of 3 beats per minute (bpm), versus a 1bpm increase with placebo (P<0.0001 for each dose versus placebo).

From the results it was concluded that, liraglutide reduces SBP in patients with T2D, including those receiving concomitant antihypertensive medication.

Practice Pearls:
  • Liraglutide once daily was associated with significant reductions in systolic blood pressure after 26 weeks compared with placebo, with decreases appearing as early as 2 weeks.
  • Reduced systolic blood pressure observed with liraglutide was weakly correlated with weight loss
  • Use of liraglutide may help lower cardiovascular risk in the setting of T2DM.

Reductions in Systolic Blood Pressure With Liraglutide in Patients With Type 2 Diabetes: Insights From a Patient-Level Pooled Analysis of Six Randomized Clinical Trials. J. Diabetes Complicat. 2014 May 01;28(3)399-405, VA Fonseca, JH Devries, RR Henry, M Donsmark, HF Thomsen, J Plutzky 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 29 May, 2014 and appeared in  CardiovascularObesityGLP-1Issue 731GLP-1 Special Editions June 2014GLP-1 Special Editions Summer 2014

Past five issues: Diabetes Clinical Mastery Series Issue 212 | GLP-1 Special Editions October 2014 | Issue 752 | SGLT-2 Inhibitors Special Edition October 2014 | Diabetes Clinical Mastery Series Issue 211 |

2014 Most Popular Articles:

Two Positive Phase 3 Trials for ITCA 650, a GLP-1 Agonist, in Type 2 Diabetes
Posted October 10, 2014
Adding an SGLT2 to Insulin Improved Control
Posted October 17, 2014
For Your Patients: Why Daily Movement Improves Your Brain Health (Part 2): Brain Hormone Changes
Posted October 17, 2014
Best Insulin Regimen for Type 1's
Posted October 10, 2014
New GLP-1 Receptor Agonist as an Alternative to Insulin Glargine?
Posted October 10, 2014
Vitamin D and Type 2 Diabetes Risk
Posted October 17, 2014
EASD: Insulin Pumps Lower Mortality Rate 29% Compared to Multiple Injections in T1DM
Posted October 03, 2014
Handbook of Diabetes, 4th Ed., Excerpt #13: Control and Complications
Posted October 13, 2014
FDA Approves Once-Weekly GLP-1 Diabetes Treatment Regimen for T2DM
Posted September 25, 2014
Non-Caloric Artificial Sweeteners May Induce Glucose Intolerance
Posted October 10, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Are your patients getting enough glucose strips to manage their diabetes?
CME/CE of the Week
Vickie Driver, DPM, MS, FACFAS

Category: Wound Care
Credits: 1.0



Search Articles On Diabetes In Control